

IN THE CLAIMS:

This listing of claims below will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-3. (canceled).

Claim 4. (currently amended) A method of lowering the blood glucose level by which comprises administering an effective dose of a growth hormone secretagogue receptor (GHS-R) GHS-R antagonist to a patient of diabetes mellitus, wherein said GHS-R antagonist is selected from the group consisting of a ghrelin analog antagonist, [D-Lys-3]-GHRP-6 and [D-Arg-1, D-Phe-5, D-Trp-7, 9, Leu-11] substance P.

Claim 5. (canceled)

Claim 6. (canceled)

Claim 7. (currently amended) A method of preventing or treating diabetes mellitus which comprises administering an effective dose of a growth hormone secretagogue receptor (GHS-R) GHS-R antagonist, wherein said GHS-R antagonist is selected from the group consisting of a ghrelin analog antagonist, [D-Lys-3]-GHRP-6 and [D-Arg-1, D-Phe-5, D-Trp-7, 9, Leu-11] substance P.

Claim 8. (currently amended) A method of preventing or treating obesity which comprises administering an effective dose of a growth hormone secretagogue receptor (GHS-R) GHS-R antagonist, wherein said GHS-R antagonist is selected from the group consisting of a ghrelin analog antagonist, [D-Lys-3]-GHRP-6 and [D-Arg-1, D-Phe-5, D-Trp-7, 9, Leu-11] substance P.

Claim 9. (currently amended) A method of suppressing appetite which comprises administering an effective dose of a growth hormone secretagogue receptor (GHS-R) GHS-R antagonist, wherein said GHS-R antagonist is selected from the group consisting of a ghrelin analog antagonist, [D-Lys-3]-GHRP-6 and [D-Arg-1, D-Phe-5, D-Trp-7, 9, Leu-11] substance P.

Claim 10. (new) A method of claim 4, wherein the GHS-R antagonist is administered centrally or peripherally.

Claim 11. (new) A method of claim 7, wherein the GHS-R antagonist is administered centrally or peripherally.

Claim 12. (new) A method of claim 8, wherein the GHS-R antagonist is administered centrally or peripherally.

Claim 13. (new) A method of claim 9, wherein the GHS-R antagonist is administered centrally or peripherally.